Huijuan Yang

Huijuan Yang

Auto-generated profile, based on publicly available information

Huijuan Yang

Department of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Cancer Research
Verified
Journal Article
Closed access
STSteven Tau
Steven Tau
MCMary D. Chamberlin
Mary D. Chamberlin
HYHuijuan Yang
Huijuan Yang
JMJonathan D. Marotti
Jonathan D. Marotti
PMPatricia C. Muskus
Patricia C. Muskus
TMTodd W Miller
Todd W Miller
Despite adjuvant treatment with endocrine therapies, estrogen receptor–positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such persister cells may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening in ER+ breast cancer cells, we identified a survival mechanism involving metabolic reprogramming with reliance upon mitochondrial respiration in endocrine-tolerant persister cells. Quantitative proteomic profiling showed reduced levels of glycolytic proteins in persisters. Metabolic tracing of glucose revealed an energy-depleted state in persisters, in which oxidative phosphorylation was required to generate ATP. A phase II clinical trial was conducted to evaluate changes in mitochondrial markers in primary ER+/HER2– breast tumors induced by neoadjuvant endocrine therapy (NCT04568616). In an analysis of tumor specimens from 32 patients, tumors exhibiting residual cell proliferation after aromatase inhibitor–induced estrogen deprivation with letrozole showed increased mitochondrial content. Genetic profiling and barcode lineage tracing showed that endocrine-tolerant persistence occurred stochastically without genetic predisposition. Pharmacologic inhibition of mitochondrial complex I suppressed the tumor-forming potential of persisters in mice and synergized with the antiestrogen drug fulvestrant to induce regression of patient-derived xenografts. These findings indicate that mitochondrial metabolism is essential in endocrine-tolerant persister ER+ breast cancer cells and warrant the development of treatment strategies to leverage this vulnerability for treating breast cancer. Significance: Persister cancer cells that survive endocrine therapy exhibit increased energetic dependence upon mitochondria for survival and tumor regrowth potential, indicating that therapies targeting this metabolic dependency could help prevent disease recurrence.




17 June 2026
Verified
Other
Open access
STSteven Tau
Steven Tau
MCMary D. Chamberlin
Mary D. Chamberlin
HYHuijuan Yang
Huijuan Yang
JMJonathan D. Marotti
Jonathan D. Marotti
PMPatricia C. Muskus
Patricia C. Muskus
TMTodd W Miller
Todd W Miller
Supplementary Table 12 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER+ Breast Cancer

17 June 2026
Verified
Other
Open access
STSteven Tau
Steven Tau
MCMary D. Chamberlin
Mary D. Chamberlin
HYHuijuan Yang
Huijuan Yang
JMJonathan D. Marotti
Jonathan D. Marotti
PMPatricia C. Muskus
Patricia C. Muskus
TMTodd W Miller
Todd W Miller
Supplementary Table 3 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER+ Breast Cancer